Trending...
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
PHILADELPHIA--(BUSINESS WIRE)--Audacy announced a multiplatform partnership with mental health innovator Genomind. This breakthrough partnership taps into Audacy's influencers and Genomind's personalized genetic insights to bring mental health conversations into the mainstream.
As part of the partnership, Audacy will leverage the deep local connection of 15 stations across eight markets – Baltimore, Dallas, Houston, Los Angeles, New York, Philadelphia, San Diego and Washington D.C. – to promote Genomind's new Mental Health Map™, the first and only consumer DNA test to offer a concise, easy-to-navigate blueprint of your genetic profile and its influence on stress and anxiety, mood, focus and memory, habits and substance use, sleep, social behavior, and eating behavior.
Audacy and Genomind align in shared commitment to end the stigma surrounding mental health. Audacy's trusted voices and influencers will serve as ambassadors for the campaign – sharing their first hand experiences, using the Mental Health Map to learn more about their genetic makeup and predispositions toward mental health and wellness traits. Audacy is also among the first to provide Genomind as an employee benefit to help drive more engagement and action in mental health and wellness.
"Mental health awareness is a major area of focus for us and a crucial pillar of our companywide social impact platform, and we're excited to further activate our commitment through this partnership with Genomind," said Sarah Harris, Vice President, Social Impact, Audacy. "We recognize our significant influence and welcome the opportunity to use our voice, coupled with Genomind's mental health expertise, innovations and technology, to help improve and save lives and continue our shared mission of ending the stigma of talking about mental health."
More on The PennZone
"Genomind works to help all of us understand our personal mental health wiring and give people new insights and tools to manage and promote personalized mental health and wellness," said Kip Olmstead, President, Genomind. "Our partnership with Audacy scales our work allowing us to bring new mental health solutions to millions of Americans who may be suffering in silence or unsure of how to get started. Audacy's leadership in mental health is impressive and we are thrilled to find such a progressive and purpose-driven partner."
Genomind will also serve as the sponsor for Audacy's "I'm Listening Daily Capsules," 60-second daily public service announcements as part of the company's yearlong "I'm Listening" mental health initiative. Genomind will also serve as the presenting sponsor of Audacy's annual "I'm Listening" broadast, a live national program that brings together artists, athletes and medical specialists every September to remind listeners it's okay to not be okay, raise awareness and end the stigma of talking about mental health.
Audacy is committed to supporting the health and success of the communities that are the heart of its business. "I'm Listening" is a part of Audacy Serves, the Company's social impact platform that raises awareness of social issues and brings communities together for good. Audacy unites with its listeners and brands to support sound communities through several pillars of impact: mental health and anti-bullying, veterans and service members, children's health, the environment, civic education, and diversity, equity and inclusion.
More on The PennZone
About Audacy
Audacy, Inc. (NYSE: AUD) is a scaled, multi-platform audio content and entertainment company with the country's best radio broadcasting group, a leader in virtually every segment of audio, and America's #1 creator of original, premium audio. Audacy engages over 170 million consumers each month, bringing people together around the news, sports, podcasts and music that matter to them. Learn more at www.audacyinc.com, Facebook (Audacy Corp) and Twitter (@AudacyCorp).
About Genomind
Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind® Professional PGx Express™, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients' mental health treatment. The Company also recently launched GenMed✓ Pro™ – Genomind's Smarter Precision Gene-Drug Interaction Software. This advanced medication management software was designed to help health professionals make safer prescribing decisions with speed and precision. In 2020 the company introduced the Genomind Mental Health Map™ – a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at https://www.genomind.com/.
As part of the partnership, Audacy will leverage the deep local connection of 15 stations across eight markets – Baltimore, Dallas, Houston, Los Angeles, New York, Philadelphia, San Diego and Washington D.C. – to promote Genomind's new Mental Health Map™, the first and only consumer DNA test to offer a concise, easy-to-navigate blueprint of your genetic profile and its influence on stress and anxiety, mood, focus and memory, habits and substance use, sleep, social behavior, and eating behavior.
Audacy and Genomind align in shared commitment to end the stigma surrounding mental health. Audacy's trusted voices and influencers will serve as ambassadors for the campaign – sharing their first hand experiences, using the Mental Health Map to learn more about their genetic makeup and predispositions toward mental health and wellness traits. Audacy is also among the first to provide Genomind as an employee benefit to help drive more engagement and action in mental health and wellness.
"Mental health awareness is a major area of focus for us and a crucial pillar of our companywide social impact platform, and we're excited to further activate our commitment through this partnership with Genomind," said Sarah Harris, Vice President, Social Impact, Audacy. "We recognize our significant influence and welcome the opportunity to use our voice, coupled with Genomind's mental health expertise, innovations and technology, to help improve and save lives and continue our shared mission of ending the stigma of talking about mental health."
More on The PennZone
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Boston Industrial Solutions Introduces Personalized Printing Training
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development
"Genomind works to help all of us understand our personal mental health wiring and give people new insights and tools to manage and promote personalized mental health and wellness," said Kip Olmstead, President, Genomind. "Our partnership with Audacy scales our work allowing us to bring new mental health solutions to millions of Americans who may be suffering in silence or unsure of how to get started. Audacy's leadership in mental health is impressive and we are thrilled to find such a progressive and purpose-driven partner."
Genomind will also serve as the sponsor for Audacy's "I'm Listening Daily Capsules," 60-second daily public service announcements as part of the company's yearlong "I'm Listening" mental health initiative. Genomind will also serve as the presenting sponsor of Audacy's annual "I'm Listening" broadast, a live national program that brings together artists, athletes and medical specialists every September to remind listeners it's okay to not be okay, raise awareness and end the stigma of talking about mental health.
Audacy is committed to supporting the health and success of the communities that are the heart of its business. "I'm Listening" is a part of Audacy Serves, the Company's social impact platform that raises awareness of social issues and brings communities together for good. Audacy unites with its listeners and brands to support sound communities through several pillars of impact: mental health and anti-bullying, veterans and service members, children's health, the environment, civic education, and diversity, equity and inclusion.
More on The PennZone
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
About Audacy
Audacy, Inc. (NYSE: AUD) is a scaled, multi-platform audio content and entertainment company with the country's best radio broadcasting group, a leader in virtually every segment of audio, and America's #1 creator of original, premium audio. Audacy engages over 170 million consumers each month, bringing people together around the news, sports, podcasts and music that matter to them. Learn more at www.audacyinc.com, Facebook (Audacy Corp) and Twitter (@AudacyCorp).
About Genomind
Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind® Professional PGx Express™, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients' mental health treatment. The Company also recently launched GenMed✓ Pro™ – Genomind's Smarter Precision Gene-Drug Interaction Software. This advanced medication management software was designed to help health professionals make safer prescribing decisions with speed and precision. In 2020 the company introduced the Genomind Mental Health Map™ – a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at https://www.genomind.com/.
0 Comments
Latest on The PennZone
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
- Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Mandeville Pests May Pose Serious Health Risks for Your Family
- A New Tale Band Makes 9/11 Tribute Song "The Twins" Free for Ceremonies and School Programs